Estrategia fármaco-invasiva en el manejo del infarto agudo al miocardio con supradesnivel del ST

Hameau D, René; Blacud M, Ricardo; Fanta A, Mario; Alvarado L, Cristobal; Hameau D, Cristobal; Olmos C, Alfonso; Pérez P, Osvaldo.
Rev. méd. Chile ; 150(12): 1619-1624, dic. 2022. ilus, tab
Artículo en Español | LILACS | ID: biblio-1515392

Documentos relacionados

  1. [Pharmaco-invasive approach in the management of acute myocardial infarction. Analysis of 144 cases].
  2. Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme.
  3. Late outcomes of ST-elevation myocardial infarction treated by pharmaco-invasive or primary percutaneous coronary intervention.
  4. [Management of acute coronary syndrome : ESC guidelines 2023].
  5. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial.
  6. [Efficacy and safety comparison between pro-urokinase and reteplase in the treatment of patients with acute ST elevation myocardial infarction].
  7. Optimized Treatment of ST-Elevation Myocardial Infarction.
  8. Fibrinolytic Therapy in Patients with Acute ST-elevation Myocardial Infarction.
  9. The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients.
  10. 16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction.